Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Inhaled Corticosteroids PA | OpenPaye…
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 5842-A

    Inhaled Corticosteroids Medical Necessity

    Customize your policy alerts

    Sign up for cvs_caremark Policy 5842-A alerts

    Get alerted when Policy 5842-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity and prior-authorization coverage for specified inhaled corticosteroids, including brand and generic products and all dosage forms and strengths unless otherwise stated. It applies to providers requesting coverage for asthma maintenance treatment and the specified compendial use of Flovent HFA for eosinophilic esophagitis.

    Policy Summary
    PayerCVS Caremark
    PolicyInhaled Corticosteroids Medical Necessity
    Policy CodePolicy 5842-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit documentation showing the applicable formulary alternative trial and inadequate response, intolerance, or contraindication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6Inhaled corticosteroid products referenced
    12 monthsAuthorization duration
    3Formulary alternatives for age 7+
    Age 4+Youngest FDA-approved age for several products

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1
    Compendial non-asthma indication

    Medical Necessity and Coverage Criteria

    Eosinophilic Esophagitis (EoE)

    Authorization may be granted when ALL of the following criteria are met:

    ALL of the following

    • The patient has a diagnosis of eosinophilic esophagitis (EoE).

      Documentation is required for approval.

    • The request is for Flovent HFA (fluticasone propionate HFA).

    Medical Necessity

    Authorization may be granted for the requested drug when ALL of the following criteria are met:

    ALL of the following

    • The requested drug is being used for an FDA-approved indication OR an indication supported in the compendia of current literature (examples: AHFS, Micromedex, current accepted guidelines).
    • The prescribed dose and quantity fall within the FDA-approved labeling or within dosing guidelines found in the compendia of current literature.
    • The patient CANNOT be treated with a formulary drug. Available Formulary Alternatives: Asmanex HFA, fluticasone furoate ellipta (generic Arnuity Ellipta), Pulmicort Flexhaler.

    Patients Age 7 Years or Older

    If the patient is 7 years of age or older, ALL of the following criteria must be met:

    ALL of the following

    • The patient is unable to take the formulary alternatives due to a trial and inadequate treatment response or intolerance, or a contraindication. Available Formulary Alternatives: Asmanex HFA, fluticasone furoate ellipta (generic Arnuity Ellipta), Pulmicort Flexhaler.

      Documentation is required for approval.

    Patients Age 5 to Less Than 7 Years

    If the patient is 5 to less than 7 years of age, the following criterion must be met:

    ALL of the following

    • The patient is unable to take the formulary alternative due to a trial and inadequate treatment response, intolerance, or a contraindication. Available Formulary Alternative: Asmanex HFA.

      Documentation is required for approval.

    Patients Younger Than 5 Years

    If the patient is less than 5 years of age, ONE of the following criteria must be met:

    ONE of

    • The request is for fluticasone propionate HFA.
    • ALL of

      • The patient CANNOT be treated with a formulary drug. Available Formulary Alternative: fluticasone propionate HFA.

        The requested drug may be granted for patients that have had prior use of brand Flovent HFA.

      • The patient had a prior trial and inadequate treatment response, intolerance, or has a contraindication to fluticasone propionate HFA or brand Flovent HFA.

        Documentation is required for approval.

    Alvesco, Arnuity Ellipta, Asmanex Twisthaler, Flovent Diskus, Flovent HFA, and Qvar Redihaler are not indicated for the relief of acute bronchospasm.

    Alvesco is not indicated for children under 12 years of age. Asmanex Twisthaler is not indicated for children less than 4 years of age.

    Initial Authorization Requirements

    Initial Therapy

    Initial authorization may be granted when all of the following criteria are met.

    Initial medical-necessity authorization

    • Indication support

      • The requested drug is used for an FDA-approved indication or an indication supported in the compendia of current literature.
    • Dose and quantity: The prescribed dose and quantity are within FDA-approved labeling or compendial dosing guidance.
    • Formulary alternative and age-specific requirements: The patient cannot be treated with the applicable formulary alternative under the applicable age-based criteria: patients age 7 years or older must be unable to take Asmanex HFA, fluticasone furoate ellipta (generic Arnuity Ellipta), or Pulmicort Flexhaler; patients age 5 to less than 7 years must be unable to take Asmanex HFA; and patients younger than 5 years must meet one of the specified fluticasone propionate HFA pathways.

    Formulary Alternative Requirements

    StepRequirementFailure criteria
    1Use applicable formulary alternatives before the requested drug. For patients age 7 years or older: Asmanex HFA, fluticasone furoate ellipta (generic Arnuity Ellipta), or Pulmicort Flexhaler. For patients age 5 to less than 7 years: Asmanex HFA.Trial and inadequate treatment response, intolerance, or contraindication to the applicable formulary alternative.
    StepRequirementFailure criteria
    1For patients younger than 5 years, use formulary fluticasone propionate HFA before the requested drug, unless the request is for fluticasone propionate HFA. Prior use of brand Flovent HFA may satisfy the prior-use pathway.Prior trial with inadequate treatment response, intolerance, or contraindication to fluticasone propionate HFA or brand Flovent HFA.

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Medical Necessity Authorization

    Prior authorization may be granted when the requested drug is used for an FDA-approved indication or an indication supported by current compendia, the prescribed dose and quantity are within FDA labeling or compendial guidance, and the patient cannot be treated with a formulary drug.

    • Document the indication, prescribed dose, quantity, and applicable formulary alternative history.
    Prior Authorization

    EoE Authorization: Flovent HFA

    For eosinophilic esophagitis (EoE), authorization may be granted when the patient has a documented EoE diagnosis and the request is for Flovent HFA (fluticasone propionate HFA).

    • Submit documentation supporting the EoE diagnosis.
    • Confirm that the requested product is Flovent HFA.

    Clinical Background

    The referenced inhaled corticosteroids are used primarily as maintenance or prophylactic therapy for asthma across specified pediatric and adult populations. Product-specific age ranges apply, including use in children as young as 4 years for several products, 5 years for Arnuity Ellipta, and 12 years for Alvesco. Flovent HFA also has a compendial use for eosinophilic esophagitis. These therapies are not intended for acute bronchospasm relief.

    Key Definition

    Eosinophilic esophagitis
    TermEosinophilic esophagitis (EoE)
    Authorization diagnosisThe patient has a diagnosis of eosinophilic esophagitis (EoE).
    Requested productFlovent HFA (fluticasone propionate HFA).
    DocumentationDocumentation is required for approval.
    Policy Summary
    PayerCVS Caremark
    PolicyInhaled Corticosteroids Medical Necessity
    Policy CodePolicy 5842-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit documentation showing the applicable formulary alternative trial and inadequate response, intolerance, or contraindication.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaInitial Authorization RequirementsFormulary Alternative RequirementsAuthorization, Documentation, and Denial RisksClinical BackgroundKey Definition

    Documentation is required where specified by the criteria.

    Note

    12-Month Approval Duration

    Under policy 5842-A, an approved authorization is granted for 12 months.

    • Duration of approval: 12 months.
    Step Therapy

    Age-Based Formulary Step Therapy: Age 7 and Older

    For patients age 7 years or older, document that the patient cannot take the applicable formulary alternatives because of a trial with inadequate treatment response, intolerance, or a contraindication.

    • Applicable formulary alternatives: Asmanex HFA, fluticasone furoate ellipta (generic Arnuity Ellipta), and Pulmicort Flexhaler.
    • Documentation is required for approval.
    Step Therapy

    Age-Based Formulary Step Therapy: Ages 5 to Under 7

    For patients age 5 to less than 7 years, document that the patient cannot take the applicable formulary alternative because of a trial with inadequate treatment response, intolerance, or a contraindication.

    • Applicable formulary alternative: Asmanex HFA.
    • Documentation is required for approval.
    Step Therapy

    Under-5 Step Therapy

    For patients younger than 5 years, authorization may be granted when the request is for fluticasone propionate HFA or when the patient cannot be treated with the applicable formulary alternative.

    • The applicable formulary alternative is fluticasone propionate HFA.
    • Prior use of brand Flovent HFA may support that the patient cannot be treated with the formulary alternative.
    Documentation Required

    EoE Documentation

    For an EoE request, submit documentation of the EoE diagnosis and confirm that the requested product is Flovent HFA (fluticasone propionate HFA).

    • EoE diagnosis documentation is required for approval.
    Documentation Required

    Formulary Alternative History

    For patients age 7 years or older, document the required trial of the applicable formulary alternative and the outcome showing inadequate treatment response, intolerance, or contraindication.

    • Alternatives to address include Asmanex HFA, fluticasone furoate ellipta (generic Arnuity Ellipta), and Pulmicort Flexhaler.
    • The patient must be unable to take the formulary alternatives.
    Documentation Required

    Under-5 Clinical History

    For patients younger than 5 years, document the prior trial and inadequate treatment response, intolerance, or contraindication to fluticasone propionate HFA or brand Flovent HFA when that history is used to support the request.

    • Documentation is required for approval.
    Denial Risk

    Unsupported Indication or Dosing

    Authorization may be denied when the requested drug is used outside an FDA-approved indication or current compendial support, or when the prescribed dose or quantity falls outside FDA labeling and compendial dosing guidance.

    • Document the supported indication and dose-and-quantity rationale.
    Denial Risk

    Formulary Alternative Available or Step Therapy Not Documented

    Authorization may be denied when the patient can be treated with a formulary alternative or when the required age-based step therapy and supporting treatment history are not documented.

    • For age 7 years or older, address Asmanex HFA, generic Arnuity Ellipta, and Pulmicort Flexhaler.
    • For ages 5 to under 7 years, address Asmanex HFA.
    • For patients younger than 5 years, address fluticasone propionate HFA, including prior brand Flovent HFA use when applicable.
    Denial Risk

    Acute Bronchospasm Use

    Requests for acute-relief treatment of bronchospasm do not meet the product limitation. The inhaled corticosteroids listed in this policy are not indicated for relief of acute bronchospasm.

    • This limitation applies to Alvesco, Arnuity Ellipta, Asmanex Twisthaler, Flovent Diskus, Flovent HFA, and Qvar Redihaler.
    • Do not submit these products as acute-relief treatment for bronchospasm.
    Prior Authorization

    Eosinophilic Esophagitis Criteria

    For EoE, authorization requires a documented EoE diagnosis, a request specifically for Flovent HFA, and satisfaction of the applicable medical-necessity and age-based formulary criteria.

    • The requested indication must be supported and the dose and quantity must be within FDA-approved labeling or current compendial guidance.
    • Where applicable, document formulary alternative trial and inadequate response, intolerance, or contraindication.
    • For patients younger than 5 years, address the fluticasone propionate HFA or brand Flovent HFA history requirements.